Figure 1.
Heme oxygenase, the rate limiting enzyme in the heme catabolic pathway, catalyzes oxidative degradation of heme to form equimolar amounts of bioactive products carbon monoxide, iron and biliverdin, which is subsequently reduced to bilirubin by biliverdin reductase.
Table 1.
Baseline characteristics of patients with hepatitis C.
Table 2.
Primer sequences for HCV RNA, target and internal control genes.
Figure 2.
ROC curve of BLVRA expression in peripheral blood leukocytes of HCV infected patients.
AUC, area under the ROC curve; ROC, Receiver Operating Charasteristic.
Table 3.
Multivariate logistic regression analysis of potential SVR predictors.
Table 4.
The impact of ribavirin-induced anemia on BLVRA expression.
Figure 3.
BLVRA expression in peripheral blood leukocytes of responders and non-SVR patients during standard antiviral therapy.
BLVRA expression was measured the day before treatment initiation (0), and 12, 24, 36 and 48 weeks after start of the standard treatment. Data represent means and standard deviations for triplicate determinations. P-values calculated between responders and non-SVR patients. BLVRA, biliverdin reductase A; PBL, peripheral blood leukocytes; SVR = responders, NVR = non-SVR patients.